For Immediate Release
Chicago, IL – December 23, 2020 –
Zacks Equity Research highlights Construction Partners ( ROAD Quick Quote ROAD - Free Report) as the Bull of the Day and Surgery Partners ( SGRY Quick Quote SGRY - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Qualcomm ( QCOM Quick Quote QCOM - Free Report) , AbbVie ( ABBV Quick Quote ABBV - Free Report) and Garmin ( GRMN Quick Quote GRMN - Free Report) .
Here is a synopsis of all five stocks:
Bull of the Day:
This is what I would call a “bifurcated” market. That is a big word to describe what is really a simple thing. There are two tales to this market. Just as the US economy is experiencing a “k-shaped” recovery, so is the stock market. Meaning, the top stocks in the market continue to be the top stocks while the bottom end of stocks continue to suffer. If you want to stick with the winners, you need to lean on the tried-and-true Zacks Rank. Stocks with strong Zacks Rank tend to outperform the broad market over time.
One such stock is today’s Bull of the Day,
Construction Partners.Construction Partners, Inc., a civil infrastructure company, engages in the construction and maintenance of roadways across Alabama, Florida, Georgia, North Carolina, and South Carolina. The company, through its subsidiaries, provides various products and services to public and private infrastructure projects, with a focus on highways, roads, bridges, airports, and commercial and residential developments.
ROAD is a Zacks Rank #1 (Strong Buy) in the Building Products – Miscellaneous industry which ranks in the Top 45% of our Zacks Industry Rank. In addition to the favorable rank, ROAD enjoys a Zacks Growth Style Score of A, and a Momentum Style Score of C, which is helping it round out with a VGM Composite Score of B.
The reason for the favorable Zacks Rank lies in the recent upside earnings estimate revisions coming from analysts on Wall Street. Over the last 30 days, 4 analysts have increased their earnings estimates for the current year, while one analyst has increased estimates for next year. The bullish sentiment has pushed up our Zacks Consensus Estimate for the current year from 80 cents to 91 cents while next year’s number has gone from 91 cents to $1.04.
Bear of the Day:
This market is nothing short of phenomenal. There have been unprecedented moves in stocks across multiple industries. More than just a post-COVID bounce back, this market is really showing what it is made of. It may seem, in a market this strong, that any name you pick will simply go straight up. But the reality of the situation is, there are some stocks out there that will be in real trouble when the euphoria dies down. I mean, stocks with weak earnings trends are going to be the ones that give up the most ground.
One way to avoid these potential pitfalls is to lean on the time-tested Zacks Rank. Stocks with low Zacks Ranks have the weakest earnings trends. These are stocks which could very well fail when investors become more cautious about where to put their money.
Zacks Rank #5 (Strong Sell) stocks have the weakest earnings trends. One such stock is today’s Bear of the Day,
Surgery Partners owns and operates a network of surgical facilities and related services in the United States. The company operates through three segments: Surgical Facility Services, Ancillary Services, and Optical Services. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of a diagnostic laboratory, multi-specialty physician practices, urgent care facilities, anesthesia services, and optical services. It also operates optical laboratory that manufactures eyewear. As of March 31, 2020, the company owned or operated a portfolio of 127 surgical facilities, including 111 ambulatory surgical centers and 16 surgical hospitals in 30 states.
COVID-related shutdowns caused analysts to cut their earnings estimates for the stock. Over the last 60 days, analysts have cut estimates for both the current year and next year. The bearish sentiment has pushed down our Zacks Consensus Estimates for the current year from a 96-cent loss to a $1.23-loss while next year’s number is off from a 50-cent loss to a 68-cent loss.
The Medical Services industry is in the Bottom 35% of our Zacks Industry Rank.
Additional content: 3 Stocks with Strong Dividends to Buy for Growth in 2021
New travel bans from the U.K. to try to prevent a highly infectious new strain of the coronavirus from spreading across more of Europe somewhat dampened the passage of the new $900 billion relief package. The second stimulus effort is less robust, but should help boost the economy heading into what will be a rough winter for many Americans and businesses amid fresh restrictions.
Nonetheless, the S&P 500 has climbed 13% since the end of October and the tech-heavy Nasdaq touched new records on Tuesday. The rise in coronavirus cases hasn’t outweighed broader optimism heading into 2021, as people in the U.S. and elsewhere begin to be vaccinated. In fact, federal officials project that around 100 million Americans will get vaccinated by February or March.
On top of the vaccine hope, the S&P 500 earnings outlook for 2021 is strong and fourth quarter estimates have improved. Meanwhile, the low interest rate environment likely means Wall Street will be hunting for returns, which should boost stocks.
Despite the positivity, it’s likely prudent to wait a bit longer before going all-in on travel and leisure stocks and harder-hit cyclicals, even though they made a comeback recently. With all of this in mind, investors might want to consider adding stocks to their 2021 portfolios that pay a solid dividend and provide exposure to growth areas…
Qualcomm is a smartphone chip making titan that’s been on an impressive run in 2020. That said, the stock fell earlier this month after reports broke that Apple has plans to work on its own modem chips. This is part of the iPhone giant’s larger in-house chip push that’s already impacted its long-standing relationship with Intel.
Luckily for QCOM, these are ambitious plans and it won’t happen for years, if ever. In fact, Qualcomm and Apple resolved their legal battle last year, which saw QCOM land a six-year licensing deal and a “multiyear” chip-supply agreement with Apple.
The agreement highlighted Qualcomm’s impressive lead in 5G chips that are vital to the rollout of the next-generation of smartphones. The firm also announced over the summer that it resolved its battle with Huawei that saw it land a new long-term licensing agreement. QCOM is coming off a quarter (Q4 FY20) that saw its revenue surge 73%.
Qualcomm also broke down sales from different segments of the market for the first time to help highlight its growth opportunities in our digitally connected world. This list included handsets, automotive, IoT, and RF front-end, with its connected devices (IoT), coming in as the second-largest segment in FY20, well behind smartphones (handsets).
Zacks estimates call for QCOM’s revenue to climb 29% in FY21 to over $30 billion, with FY22 projected to come in another 7.3% higher. This would mark its best top-line expansion since 2013 and show a strong return to growth after its FY20 sales dipped slightly. Meanwhile, its adjusted earnings are expected to climb 69% and 10.3%, respectively over this stretch. Qualcomm, which is a Zacks Rank #3 (Hold) at the moment, has consistently topped our EPS estimates and its bottom-line outlook has improved.
Qualcomm shares have climbed 65% in the last year to crush the Wireless Equipment industry’s 36% average. Despite its run, QCOM trades at a discount to the broader tech industry at 22.3X forward 12-month earnings vs. 28X. Qualcomm’s 1.8% dividend yield tops the S&P 500’s 1.6% average, Microsoft’s 1.0%, and the 30-year U.S. Treasury’s 1.7%. Meanwhile, 12 of the 20 brokerage ratings Zacks has for QCOM come in at a “Strong Buy,” and it trades 10% below its recent December highs.
AbbVie completed its $63 billion acquisition of Allergan in May 2020. The deal added Botox and other popular drugs to its expanding roster of therapeutics that span a wide variety of illnesses and diseases. ABBV’s R&D pipeline is also strong. This should all help ABBV deal with the fact that its patent protections for Humira, one of the world’s top-selling drugs, are running out. Biosimilars are already available outside of the U.S., with competition set to start stateside in 2023.
Last quarter, global Humira sales climb 4%, driven by 8% growth in the U.S., with international sales down 9%. ABBV’s overall Q3 revenue surged 52%, driven by Allergan’s inclusion. Zacks estimates project that the pharmaceutical giant’s sales will jump 37% in FY20 to $46 billion and another 18% in FY21. The firm’s adjusted earnings are projected to climb 17% this year and another 16% in FY21.
ABBV shares have climbed 15% in the past 12 months to crush the Large-Cap Pharma industry’s 1% average. This includes a 20% surge since the end of October. And despite the recent positivity, AbbVie trades 11% below its 2018 highs. Furthermore, the stock trades at a solid discount to its industry at 8.6X forward 12-month earnings vs. 14.2X.
AbbVie also continually lifts its dividend. For instance, it raised its payout by 10% to $1.30 a share last quarter, with its next dividend payable on February 16 to shareholders of record as of January 15. This pushes its yield up to 5.0% to destroy its industry’s 2.3% average. ABBV’s valuation and its dividend helped it attract Warren Buffett and Berkshire Hathaway’s attention in the third quarter, as the firm bought up pharmaceutical stocks.
ABBV is a Zacks Rank #3 (Hold) right now that earns “A” grades for Value and Momentum and a “B” for Growth in our Style Scores system. The company has also seen more positive earnings revisions recently, and 12 of the 18 brokerage recommendations Zacks has for AbbVie come in at a “Strong Buy.”
Garmin’s in-car GPS devices, smartwatches, and fitness trackers that compete against the likes of Apple and Fitbit have helped it become a household name. That said, its in-car-focused devices have become less of a hit in the smartphone age. Luckily, GRMN is well diversified and its expansive portfolio also features fish finders, advanced radars for aviation and boating, and many other higher-end offerings and more commercial focused tech products.
Garmin topped our Q3 estimates at the end of October, with sales up 19% to $1.1 billion. Its top-line growth was driven by serious expansion in its marine (+54%), fitness (+34%), and outdoor (+30%) units. And it is poised to benefit from a growing digital fitness market that includes Peloton, lululemon’s Mirror, and others. “Demand for active lifestyle products fueled strong revenue growth resulting in record revenue and profits for the quarter,” CEO Cliff Pemble said in prepared remarks.
Zacks estimates call for Garmin’s sales to climb 7% in FY20 to reach $4 billion, with FY21 projected to pop another 7%. These estimates would come on top of FY19’s 12% growth and match FY18’s sales growth. GRMN’s adjusted earnings outlook calls for similar expansion during this stretch. Garmin’s earnings revisions positivity helps the stock land a Zacks Rank #2 (Buy) right now, and it has consistently beat our EPS estimates, including huge beats in the last two quarters.
GRMN has soared 225% in the last five years to crush the broader tech sector’s 137%. More recently, Garmin stock is up 22% in 2020 and nearly 30% in the last three months. Garmin also trades at a discount against the tech sector and it closed Q3 with around $2.7 billion in cash and marketable securities. Plus, Garmin’s 2.1% dividend yield tops the 30-year U.S. Treasury and the S&P 500’s average and it’s part of an industry that rests in the top 25% of our over 250 Zacks industries.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>
Follow us on Twitter:
Join us on Facebook:
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit
http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.